You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Peptide inhibitors of coronavirus entry

    SBC: Autoimmune Technologies, LLC            Topic: NIAID

    DESCRIPTION (provided by applicant): The broad long-term objectives of the proposed work are to develop effective medical countermeasures to be used for the treatment of viral infectious disease caused by exposure to human coronaviruses. The work will focus on the discovery and development of peptide-based therapeutics for the treatment of persons infected with the newly identified Middle Eastern ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  2. Calcaftor, a CFTR stabilizer for Cystic Fibrosis treatment

    SBC: CALISTA THERAPEUTICS INC            Topic: NIDDK

    DESCRIPTION (provided by applicant): Calista Therapeutics has invented Calcaftor, a first-in-class peptide drug that can treat all Cystic Fibrosis (CF) patients. Calcaftor is validated in the gold standard pre-clinical model of CF using F508 -CFTR lung tissue harvested from CF transplant patients. Results from this model demonstrated a gt25 hour duration of action that enables once daily inhaled n ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  3. Inter-alpha-inhibitors in Hypoxic-Ischemic Brain Injury

    SBC: PROTHERA BIOLOGICS, INC.            Topic: NINDS

    DESCRIPTION (provided by applicant): Neonatal hypoxia-ischemia (HI) remains a major cause of acute perinatal brain injury, leading ultimately to neurologic dysfunction manifesting as cerebral palsy, mental retardation, and epilepsy. Cerebral oxygen deprivation and/or reduced blood flow due to umbilical cord occlusion, prolonged labor, and/or intracranial hemorrhage produce an inflammatory respons ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  4. Novel coatings releasing synergistic polyphenols promote vascular healing

    SBC: REQUISITE BIOMEDICAL, LLC            Topic: NHLBI

    PROJECT SUMMARY Cardiovascular disease (CVD) remains the number one cause of death in the U.S. Left untreated, CVD can result in the occlusion of key arteries that can precipitate a major cardiac event. Clinicians routinely correct arterial blockages mechanically using a balloon expansion of the lesioned area and placement of a metallic stent to help keep the arteries open. However, the overstretc ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  5. IGF::OT::IGF High-Impact Substance Abuse Prevention Technologies. SBIR Phase I. Period of Performance 7/16/2014-1/15/2015

    SBC: Pro-Change Behavior Systems, Inc.            Topic: NIDA

    The overarching objective of this project is to develop an innovative technological tool that will facilitate the implementation of an evidence-based substance abuse prevention program and related health behavior risk programs among military personnel. PUBLIC HEALTH RELEVANCE

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  6. A NOVEL ELISA FOR THE DETECTION OF ANTIBODIES TO HIV-1

    SBC: Aug, Inc.            Topic: N/A

    THE LONG-TERM OBJECTIVE OF THIS CLINICAL RESEARCH IS TO FURTHER DEVELOP A NOVEL ELISA FOR THE DETECTION OF ANTIBODIES TO HIV-1 ENVELOPE GLYCOPROTEINS. THE UTILIZATION OF NATIVE ENVLOPE HIV-1 GLYCOPROTEINS OFFERS THE POSSIBILITY OF DETECTING ANTIBODIES IN PATIENT ERA TO A BROADER RANGE OF ANTIGENIC DETERMINANTS INCLUDING CONFORMATIONAL EPITOPES. THE ENHANCED SENSITIVITY OF THIS NOVEL ELISA WILL BE ...

    SBIR Phase I 1992 Department of Health and Human Services
  7. ARYL HYDRAZONES WITH ANTICANCER ACTIVITIES

    SBC: DEKK-TEC INC            Topic: N/A

    SUBSTITUTED BENZOPHENONE PHENYLHYDRAZONES HAVE BEEN IDENTIFIED THAT POSSESS ANTIESTROGEN ACTIVITIES WITH ABSENT ESTROGENICITY. 4, 4'-DIHYDROXYBENZOPHENONE-2, 4-DINITROPHENYLHDRAZONE (A-007) HAS DEMONSTRATED ANTIESTROGENIC ACTIVITIES AT LOW CONCENTRATIONS AND CYTOTOXIC ACTIVITIES AT HIGHER CONCENTRATIONS IN ESTROGEN INDEPENDENT BREAST CANCERS. A-007 IS PRESENTLY BEING PREPARED FOR CLINICAL STUDIES. ...

    SBIR Phase I 1992 Department of Health and Human Services
  8. EVALUATION OF GALACTOSYLTRANSFERASE II AS A TUMOR MARKER

    SBC: Gentest Laboratories            Topic: N/A

    RECENT REPORTS BY SEVERAL INVESTIGATORS INDICATED SERUM LEVELS OF THE ISOENZYME OF B1-4-GALACTOSYLTRANSFERASE (GTII) CORRELATED WITH THE TUMOR BURDEN OF METASTIC CANCER PATIENTS. IN OVARIAN TUMOR PATIENTS, SUCCESSFUL CANCER THERAPY RESULTED IN DECREASED LEVELS OF SERUM GTII. PRELIMINARY STUDIES INDICATED THE VARIATION BETWEEN CANCER-ASSOCIATED AND NORMAL SERUM GT IS NOT IN THE GLYCOSYLATION BUT IN ...

    SBIR Phase I 1992 Department of Health and Human Services
  9. CPR FOR FAMILIES\VIDEOTAPE DEVELOPMENT

    SBC: Institute For Behavioral Medic            Topic: N/A

    ALTHOUGH EARLY INITIATION OF CPR DOES IMPROVE SURVIVAL, THE PUBLIC HEALTH IMPACT HAS BEEN MINIMIZED BY NOT TARGETING THE TRAINING OF INDIVIDUALS WHO LIVE WITH PATIENTS AT INCREASED RISK FOR SUDDEN DEATH. BASED ON RECENT CONCERNS REGARDING DISEASE TRANSMISSION THROUGH MOUTH-TO-MOUTH CONTACT, WE SPECULATE THAT BYSTANDER CPR RATES ARE DECLINING AND WILL IMPACT NEGATIVELY ON SURVIVAL RATES. DESPITE SU ...

    SBIR Phase II 1992 Department of Health and Human Services
US Flag An Official Website of the United States Government